Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2011

View Archived Issues

New phase IIa data presented on sifalimumab in systemic lupus erythematosus

Sunitinib has limited efficacy in advanced adrenocortical carcinoma in phase II trial

Scientists at Pfizer prepare novel phosphodiesterase 8B inhibitors

New tubulin inhibitors synthesized by R&D-Biopharmaceuticals

Plexxikon presents novel protein kinase inhibitors

Tekmira secures licenses to two validated oncology targets from Alnylam Pharmaceuticals

Incyte seeks FDA approval for ruxolitinib in myelofibrosis

First subject enrolled in phase II study of ALD-401 in ischemic stroke

Ipsen discontinues development of irosustat as monotherapy

GTx confirms phase III program design for ostarine in NSCLC

BAY-80-6946 is well tolerated in first-in-human trial in advanced solid tumors

VTX-2337 exhibits safety/tolerability in phase I trial in advanced solid tumors

Auspex Pharmaceuticals claims new antagonists of dopamine D2 and/or D3 receptor

Belgian scientists disclose new nicotinic acetylcholine receptor modulators

New PARP-1 inhibitor JI-1260 is a candidate for stroke therapy

Sound Pharmaceuticals begins trial of SPI-1005 for hearing loss induced by loud music

BioMarin begins phase III trial of amifampridine phosphate in LEMS

Oxygen Biotherapeutics gains approval to expand STOP-TBI to India

Nektar Therapeutics reports interim phase I data on NKTR-181

Biogen Idec receives European approval for Avonex Pen

BioMimetic Therapeutics completes enrollment in trial of Augment Rotator Cuff Graft

Johnson & Johnson begins phase II study of JNJ-40411813 in schizophrenia

Emergent BioSolutions acquires anticancer candidate zanolimumab from TenX BioPharma

Almirall launches Actikerall in U.K. for treatment of actinic keratosis

Bayer HealthCare submits MAA to EMA for VEGF Trap-Eye in wet AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026